← Leaderboards
Fengzhi Li
Roswell Park Cancer Institute Corp
$3,917,805
Attributed
$5,393,449
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,393,449 · 7
By mechanism
R44$2,326,369 · 1
R01$1,866,114 · 2
R43$624,919 · 2
R21$406,247 · 1
R03$169,800 · 1
Top collaborators
- Xiang Ling6 shared
Others in their field
Top investigators on “Survivin”
- Dario C. Altieri · Wistar Institute$15,749,150
- Maciej S Lesniak · Northwestern University$9,074,165
- Gary A Piazza · Southern Research Institute$6,260,773
- Mien-Chie Hung · University Of Texas Md Anderson Can Ctr$5,939,819
- Vladimir P Torchilin · Northeastern University$5,532,741
- Michael G Brattain · University Of Texas Hlth Sci Ctr San Ant$5,273,572
Research focus
SurvivinMalignant NeoplasmsCancer CellProteinsBirc4 GeneInhibitor/AntagonistApoptosis InhibitorPharmaceutical PreparationsToxic EffectMediatingInhibition Of ApoptosisTumorMutationResistanceDosePlayResponseAnimal ModelFamilyCancer TypeDesignCancer PatientRadiation ResistanceClinical Trials
Grant awards (17)
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials$400,000
R43 · FY2023 · CA
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma$224,919
R43 · FY2018 · CA
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$210,000
R44 · FY2018 · CA
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$988,326
R44 · FY2016 · CA
A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins$84,900
R03 · FY2016 · CA · contact PI
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$903,055
R44 · FY2015 · CA
An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer$184,658
R21 · FY2015 · CA · contact PI
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$224,988
R44 · FY2014 · CA
An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer$221,589
R21 · FY2014 · CA · contact PI
A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins$84,900
R03 · FY2014 · CA · contact PI
PDEF and survivin: cancer prognosis, initiation, progression and metastasis$339,039
R01 · FY2010 · CA · contact PI
PDEF and survivin: cancer prognosis, initiation, progression and metastasis$335,208
R01 · FY2009 · CA · contact PI
Survivin expression and cancer cell drug resistance$236,953
R01 · FY2008 · CA · contact PI
Survivin expression and cancer cell drug resistance$234,402
R01 · FY2007 · CA · contact PI
Survivin expression and cancer cell drug resistance$238,851
R01 · FY2006 · CA · contact PI
Survivin expression and cancer cell drug resistance$242,062
R01 · FY2005 · CA
Survivin expression and cancer cell drug resistance$239,599
R01 · FY2004 · CA